GO:1990051 activation of protein kinase C activity: Signaling Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990051 describes the biological process that initiates the activity of inactive protein kinase C (PKC) enzymes.
• PKC activation is typically triggered by lipid second messengers such as diacylglycerol (DAG) and calcium, leading to membrane recruitment and conformational changes.
• Key PKC isoforms (e.g., PRKCA, PRKCE, PRKCZ) regulate diverse cellular responses including proliferation, differentiation, and synaptic plasticity.
• Dysregulated PKC activation is implicated in cancer, diabetes, and neurological disorders.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of PKC isoform-specific functions.
• EDITGENE provides comprehensive CRISPR services to study PKC activation in disease-relevant cell models.
Description
Protein kinase C (PKC) is a family of serine/threonine kinases that play central roles in signal transduction. The Gene Ontology term GO:1990051, activation of protein kinase C activity, refers to any process that initiates the activity of the inactive enzyme PKC. This activation is a critical step in many cellular pathways, converting extracellular signals into intracellular responses. Understanding how PKC is activated is essential for deciphering mechanisms of cell growth, differentiation, and metabolism. PKC activation is triggered by diverse stimuli, including hormones, growth factors, and neurotransmitters, often through the generation of lipid second messengers like diacylglycerol (DAG). Once activated, PKC phosphorylates target proteins, thereby modulating their function. The specificity of PKC signaling is determined by the isoform involved, its subcellular localization, and the duration of the signal. Given its broad involvement in physiology, aberrant PKC activation contributes to numerous diseases, making it a focal point for therapeutic intervention. Researchers study PKC activation using biochemical assays, imaging, and genetic models to uncover its precise roles in health and disease.
activation of protein kinase C activity At A Glance
| GO ID | GO:1990051 |
|---|---|
| GO term | activation of protein kinase C activity |
| Ontology | biological_process |
| Synonym | PKC activation, protein kinase C activation |
| Major function | Initiation of PKC enzyme activity, enabling phosphorylation of downstream targets |
| Definition | Any process that initiates the activity of the inactive enzyme protein kinase C. |
| Related cellular component | Plasma membrane, cytoplasm, nucleus |
| Related molecular function | Protein serine/threonine kinase activity, diacylglycerol binding, calcium binding |
What Is GO:1990051?
GO:1990051 (activation of protein kinase C activity) is defined as any process that initiates the activity of the inactive enzyme protein kinase C. This encompasses the molecular events that convert PKC from a dormant state to an active kinase capable of phosphorylating substrates. Activation often involves binding of cofactors such as diacylglycerol (DAG) and calcium, which induce conformational changes and membrane translocation. The term is a biological process and is synonymous with PKC activation and protein kinase C activation.
Why Is activation of protein kinase C activity Important in Cell Biology?
PKC activation is a pivotal event in signal transduction, influencing a wide array of cellular processes such as proliferation, differentiation, apoptosis, and synaptic plasticity. Dysregulation of PKC activation is linked to cancer, diabetes, and neurodegenerative diseases, making it a prime target for drug discovery. Understanding the precise mechanisms of PKC activation can reveal new therapeutic strategies and biomarkers.
• PKC activation regulates cell proliferation and survival, with implications for cancer.
• It is essential for synaptic plasticity and memory formation, linking to neurodegeneration.
• PKC activation modulates insulin signaling and glucose uptake, relevant to type 2 diabetes.
• It plays a role in immune cell activation and cytokine production.
• PKC isoforms are involved in cardiac hypertrophy and heart failure.
• Activation of PKC by tumor promoters like phorbol esters is a classic model of carcinogenesis.
• PKC activation influences ion channel activity and muscle contractility.
• It is a key node in G-protein-coupled receptor and tyrosine kinase receptor signaling.
• PKC activation can be targeted by small molecule inhibitors or activators for therapeutic benefit.
• CRISPR screens can identify novel regulators of PKC activation.
What Happens During activation of protein kinase C activity?
Signal-induced recruitment to membranes
In simple terms: PKC moves to the cell membrane when a signal arrives.
Inactive PKC resides in the cytoplasm. Upon stimulation, second messengers such as diacylglycerol (DAG) and calcium are generated, causing PKC to translocate to the plasma membrane. This recruitment is mediated by binding of DAG to the C1 domain and calcium to the C2 domain of PKC. Membrane association is a prerequisite for activation.
Conformational change and cofactor binding
In simple terms: PKC changes shape and binds helper molecules to become active.
Binding of DAG and calcium induces conformational changes that release the pseudosubstrate domain from the catalytic site, allowing substrate access. Phosphatidylserine also contributes to membrane anchoring and allosteric activation. These events convert PKC to a catalytically competent state.
Phosphorylation and maturation
In simple terms: PKC gets phosphorylated to stabilize its active form.
Full activation often requires phosphorylation of PKC at specific residues by upstream kinases such as PDK1. This phosphorylation stabilizes the enzyme and modulates its activity and localization. For example, PKC-zeta is phosphorylated in response to insulin and phosphatidylinositol-3,4,5-trisphosphate.
Substrate phosphorylation and downstream signaling
In simple terms: Active PKC phosphorylates other proteins to pass on the signal.
Once active, PKC phosphorylates serine/threonine residues on target proteins, thereby altering their function. This can lead to activation of cascades such as the Ras-MAPK pathway, as seen in T cells where PKC activates RasGRP1. PKC also regulates transcription factors like STAT3.
Termination and downregulation
In simple terms: The signal is turned off to prevent overactivity.
PKC activation is transient and terminated by dephosphorylation, degradation, or negative feedback. Prolonged activation can lead to downregulation, which is important to prevent pathological signaling. The balance between activation and termination is crucial for normal cellular function.
Key Genes Involved in GO:1990051 activation of protein kinase C activity
The following genes encode proteins that are directly involved in or regulate the activation of protein kinase C activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRKCA | Encodes PKC-alpha, a classical PKC isoform activated by DAG and calcium | Implicated in cancer, cardiac hypertrophy, and synaptic plasticity |
| PRKCB | Encodes PKC-beta, involved in immune responses and glucose metabolism | Target for diabetes and lymphoma research |
| PRKCE | Encodes PKC-epsilon, activated by DAG, involved in cardiac protection | Studied in heart failure and ischemic preconditioning |
| PRKCZ | Encodes PKC-zeta, an atypical PKC activated by PI3K products | Linked to insulin resistance and type 2 diabetes |
| PRKCD | Encodes PKC-delta, involved in apoptosis and immune signaling | Research in cancer and autoimmune diseases |
| PRKCH | Encodes PKC-eta, involved in T cell activation | Studied in immune disorders |
| PRKCQ | Encodes PKC-theta, critical for T cell activation | Target for immunosuppression |
| DGK | Diacylglycerol kinase, regulates DAG levels and thus PKC activation | Modulates PKC signaling in cancer and immune cells |
| PLCB | Phospholipase C beta, generates DAG and IP3 | Upstream regulator of PKC in GPCR signaling |
| PLCG | Phospholipase C gamma, generates DAG in response to RTK activation | Key node in growth factor signaling |
| PDPK1 | Phosphoinositide-dependent kinase 1, phosphorylates and activates PKC | Central to PKC maturation |
| RASGRP1 | Ras guanine nucleotide-releasing protein 1, activated by PKC | Links PKC to Ras-MAPK pathway in T cells |
| STAT3 | Signal transducer and activator of transcription 3, phosphorylated by PKC | Mediates cytokine signaling |
| PYK2 | Proline-rich tyrosine kinase 2, activated by PKC-epsilon | Involved in cardiac signaling |
| ATP1A1 | Na+,K+-ATPase, regulated by PKC and AMPK | Studied in muscle physiology |
| TRPV4 | Transient receptor potential cation channel V4, modulated by PKC | Role in mechanotransduction |
| NOS3 | Endothelial nitric oxide synthase, phosphorylated by PKC | Vascular function |
How Is activation of protein kinase C activity Regulated?
PKC activation is tightly regulated by multiple mechanisms. Upstream, phospholipases (PLCB, PLCG) hydrolyze phosphatidylinositol 4,5-bisphosphate to generate DAG and IP3, which mobilize calcium and recruit PKC to membranes. Diacylglycerol kinases (DGKs) phosphorylate DAG to phosphatidic acid, thereby terminating PKC activation. Protein phosphatases dephosphorylate PKC, reversing its active state. Additionally, PKC activity is modulated by phosphorylation by PDK1 and autophosphorylation. In disease states such as diabetes, PKC-zeta activation by insulin is defective, contributing to insulin resistance. Thus, PKC activation is controlled at the levels of second messenger production, post-translational modifications, and subcellular localization.
activation of protein kinase C activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRKCA | Cancer, cardiac hypertrophy | Knockout mice, cancer cell lines |
| PRKCZ | Type 2 diabetes, insulin resistance | Muscle cells, knockout models |
| PRKCQ | Autoimmune diseases, T cell activation | Jurkat T cells, knockout mice |
| PRKCE | Heart failure, ischemic injury | Cardiomyocytes, transgenic mice |
| PRKCD | Cancer, apoptosis | Knockout cell lines, xenografts |
PKC activation in cancer
Aberrant PKC activation promotes tumorigenesis by stimulating proliferation, survival, and invasion. For example, PKC-alpha and PKC-epsilon are overexpressed in various cancers, and their activation correlates with poor prognosis. Tumor promoters such as phorbol esters directly activate PKC, mimicking DAG, and have been used to study carcinogenesis. Targeting PKC activation with inhibitors is a therapeutic strategy in clinical trials.
PKC activation in diabetes and metabolic disorders
Defective PKC activation contributes to insulin resistance in type 2 diabetes. In muscle from diabetic patients, insulin fails to activate PKC-zeta, but treatment with rosiglitazone or exercise ameliorates this defect. PKC isoforms also regulate glucose uptake and lipid metabolism, making them attractive targets for metabolic disease.
PKC activation in neurological disorders
PKC activation is critical for synaptic plasticity and memory. Dysregulation of PKC signaling is implicated in Alzheimer's disease and other neurodegenerative conditions. The role of PKC in long-term potentiation provides a model for understanding cognitive decline.
PKC activation in immune and inflammatory diseases
PKC isoforms, particularly PKC-theta and PKC-epsilon, are essential for T cell activation and cytokine production. The DAG-PKC-RasGRP1 pathway links antigen receptor stimulation to Ras activation in T cells. PKC also mediates thyrotropin-induced STAT3 activation in thyroid cells. Inhibitors of PKC are being explored for autoimmune diseases.
From activation of protein kinase C activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PRKCA affect tumor growth? | PRKCA knockout cancer cell line |
| How does a point mutation in PRKCZ affect insulin signaling? | PRKCZ point-mutant knock-in cells |
| Can we tag endogenous PKC-epsilon to track localization? | Knock-in of fluorescent tag at PRKCE locus |
| What is the effect of PKC-theta overexpression on T cell activation? | PRKCQ overexpression in Jurkat cells |
| Which genes regulate PKC activation in a genome-wide screen? | CRISPR library screening in reporter cells |
| Does a disease-associated SNP in PRKCB alter kinase activity? | Point mutation knock-in in relevant cell type |
How to Study the activation of protein kinase C activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Kinase assay | Phosphorylation of substrate | Measure PKC activity in vitro |
| Western blot | Phosphorylation of PKC or substrates | Assess activation status in cells |
| Live-cell imaging | Translocation of PKC | Real-time activation dynamics |
| Phosphoproteomics | Global phosphorylation changes | Identify downstream targets |
| CRISPR knockout screen | Gene essentiality for PKC activation | Discover novel regulators |
| RNA-seq | Transcriptional changes | Downstream gene expression |
| FRET biosensors | Conformational changes of PKC | Measure activation in live cells |
Biochemical kinase assays
In vitro kinase assays measure PKC activity by detecting phosphorylation of specific substrates using radioactive ATP or phospho-specific antibodies. These assays are used to validate activation in response to stimuli or inhibitors.
Live-cell imaging of PKC translocation
Fluorescently tagged PKC (e.g., GFP-PKC) allows real-time monitoring of translocation from cytoplasm to membrane upon activation. This method reveals spatiotemporal dynamics of PKC activation.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics identifies downstream targets and phosphorylation sites following PKC activation, providing a systems-level view of signaling networks.
CRISPR screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate PKC activation. For example, a screen for regulators of Ras activation downstream of PKC in T cells.
How CRISPR Can Be Used to Study GO:1990051 activation of protein kinase C activity
Knockout
CRISPR knockout of specific PKC genes (e.g., PRKCA, PRKCZ) eliminates the protein, allowing researchers to study loss-of-function phenotypes. For example, knocking out PRKCZ in muscle cells can reveal its role in insulin signaling. Knockout models are essential for validating drug targets.
Point Mutation
Introducing point mutations (e.g., kinase-dead or constitutively active) into PKC genes via CRISPR allows precise interrogation of activation mechanisms. For instance, mutating the pseudosubstrate domain can create a constitutively active PKC, while mutating the ATP-binding site yields a kinase-dead version.
Knock-in
Knock-in of tags (e.g., GFP, HA) or disease-associated variants into endogenous PKC loci enables tracking of protein localization and function under physiological conditions. This approach is valuable for studying PKC activation dynamics in live cells.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can increase PKC levels to study gain-of-function effects. Overexpression of PKC-epsilon in cardiomyocytes, for example, mimics cardiac hypertrophy. This method helps identify downstream pathways.
How EDITGENE Supports activation of protein kinase C activity Research
Researchers studying activation of protein kinase C activity-related genes often need to determine whether a candidate gene is causally involved in PKC signaling, and CRISPR-based models provide the most direct approach. EDITGENE offers a comprehensive suite of services to generate and characterize such models.
Contact EDITGENE today to design your custom CRISPR model for activation of protein kinase C activity research.
Frequently Asked Questions About activation of protein kinase C activity
What is activation of protein kinase C activity?
It is the biological process (GO:1990051) that initiates the activity of inactive protein kinase C enzymes, typically through binding of cofactors like diacylglycerol and calcium.
What genes are involved in activation of protein kinase C activity?
Key genes include PRKCA, PRKCB, PRKCE, PRKCZ, and upstream regulators like PLCB, PLCG, and PDPK1.
How is protein kinase C activated?
PKC is activated by recruitment to membranes via DAG and calcium, followed by conformational changes and phosphorylation.
What diseases are associated with PKC activation?
Dysregulated PKC activation is linked to cancer, type 2 diabetes, neurodegenerative diseases, and autoimmune disorders.
What are the synonyms for GO:1990051?
The synonyms are PKC activation and protein kinase C activation.
Which PKC isoform is involved in insulin resistance?
PKC-zeta (PRKCZ) activation by insulin is defective in type 2 diabetes.
How can CRISPR be used to study PKC activation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of PKC genes to study their function.
What methods measure PKC activation?
Kinase assays, Western blot, live-cell imaging, and phosphoproteomics are commonly used.
Is PKC activation important for memory?
Yes, PKC activation is critical for long-term potentiation, a cellular correlate of memory.
What is the role of DAG in PKC activation?
Diacylglycerol (DAG) binds to PKC, recruiting it to membranes and inducing conformational changes that activate the kinase.
Conclusion
GO:1990051 activation of protein kinase C activity is a fundamental biological process that governs diverse cellular responses. Its dysregulation underlies major human diseases, making it a key research focus. Advances in CRISPR technology and biochemical assays continue to unravel the complexities of PKC activation, offering new avenues for therapeutic intervention. EDITGENE supports this research with tailored CRISPR models and screening services.
References
- 1. Benziane B et al.. 2012. Activation of AMP-activated protein kinase stimulates Na+,K+-ATPase activity in skeletal muscle cells.. J Biol Chem 287(28):23451-63 PMID: 22610379
- 2. Bayer AL et al.. 2003. Protein kinase C epsilon-dependent activation of proline-rich tyrosine kinase 2 in neonatal rat ventricular myocytes.. J Mol Cell Cardiol 35(9):1121-33 PMID: 12967635
- 3. Couturier A et al.. 1984. Further characterization of tumor-promoter-mediated activation of protein kinase C.. Biochem Biophys Res Commun 121(2):448-55 PMID: 6233976
- 4. Ford DA et al.. 1989. Activation of protein kinase C by naturally occurring ether-linked diglycerides.. J Biol Chem 264(23):13818-24 PMID: 2760045
- 5. Beeson M et al.. 2003. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.. Diabetes 52(8):1926-34 PMID: 12882907
- 6. Park YJ et al.. 2002. Involvement of the protein kinase C pathway in thyrotropin-induced STAT3 activation in FRTL-5 thyroid cells.. Mol Cell Endocrinol 194(1-2):77-84 PMID: 12242030
- 7. Linden DJ et al.. 1989. The role of protein kinase C in long-term potentiation: a testable model.. Brain Res Brain Res Rev 14(3):279-96 PMID: 2679942
- 8. Roose JP et al.. 2005. A diacylglycerol-protein kinase C-RasGRP1 pathway directs Ras activation upon antigen receptor stimulation of T cells.. Mol Cell Biol 25(11):4426-41 PMID: 15899849
